FMS

Business Context and Reporting Period

Company: Fresenius Medical Care AG & Co. KGaA
Filing Type: Form 6-K (Interim Report)
Reporting Period: Three and nine months ended September 30, 2019
Business Overview: The world's largest kidney dialysis company, providing dialysis care, related services, and manufacturing health care products globally. Operations are segmented into North America, EMEA, Asia-Pacific, and Latin America.

Key Financial Metrics (Nine Months Ended Sept 30, 2019)

Note: Operating income and net income declines are primarily driven by the absence of a €830M gain from the divestiture of Care Coordination activities (Sound) in the prior year and the implementation of IFRS 16.

Material Changes vs. Prior Period

• Revenue Growth: Consolidated revenue increased 5% (1% at constant currency). Growth was driven by same-market treatment growth (3.6%) and acquisitions, partially offset by the divestiture of Sound in 2018.
• Profitability Decline: Operating income margin decreased from 19.8% to 12.8%. The primary driver was the €830M gain on divestitures in 2018, which was not repeated in 2019. Adjusted operating income (excluding one-time items) remained relatively stable.
• IFRS 16 Implementation: The adoption of IFRS 16 (Leases) in 2019 significantly impacted the balance sheet, increasing total assets by 26% and adding lease liabilities. It also altered the income statement structure, replacing straight-line rent expense with depreciation and interest.
• Acquisition of NxStage: Completed in February 2019, this acquisition contributed to revenue growth in the North America segment but added integration costs and operating losses in the short term.
• North America Segment: Operating income dropped 41% year-over-year, heavily influenced by the prior year's divestiture gain and the "ESCO effect" (reduction in shared savings revenue).

Guidance, Outlook, and Risks

Outlook (2019 Full Year at Constant Currency)

• Revenue Growth: 3% - 7%
• Operating Income Growth: (1)% - 3%
• Net Income Growth: (2)% - 2%
• Capital Expenditures: €1.0 - €1.2 billion
• Net Leverage Ratio: Target < 2.5x

Key Risks and Contingencies

• Reimbursement Risk: Significant exposure to U.S. Medicare reimbursement rates (approx. 33% of revenue). Potential changes in the ESRD Prospective Payment System (PPS) and the ESRD Treatment Choices (ETC) model pose uncertainty.
• Legal and Regulatory: Ongoing investigations and litigation, including False Claims Act matters and a recent settlement with the DOJ/SEC regarding FCPA violations (€231.7M penalty paid in 2019).
• Internal Control Weakness: Management identified a material weakness in internal controls over financial reporting related to revenue recognition for fee-for-service arrangements under legal consideration. Remediation is underway.
• Currency Fluctuations: Significant portion of revenue is generated in U.S. dollars; exchange rate volatility impacts reported results.

Investor Verification Checklist

• Adjusted vs. Reported Earnings: Verify the reconciliation of reported operating income to "Adjusted" operating income to understand the impact of the NxStage acquisition, IFRS 16, and the prior year Sound divestiture gain.
• North America Care Coordination: Review the specific performance of the Care Coordination segment, which reported a loss in Q3 2019, and the impact of the ESCO shared savings model.
• Debt and Liquidity: Confirm the net leverage ratio trajectory, noting the increase to 3.2x due to IFRS 16 lease liabilities and the reduction in cash balances.
• Revenue Recognition Controls: Assess the status of remediation efforts for the identified material weakness regarding revenue recognition and variable consideration constraints.
• NxStage Integration: Monitor the integration progress and the timeline for NxStage to move from an operating loss to profitability as projected in the outlook.